Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 15/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | MERTK | Q12866 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487165 | 0.87 | AXL (0.60) | AXLRETMETKDRPDGFRB | |
| SCHEMBL1132601 | 0.87 | AXL (0.60) | AXLRETMETKDRPDGFRB | |
| SCHEMBL30066135 | 0.85 | AXL (0.55) | AXLMETKDRPDGFRBPDGFRA | |
| SCHEMBL1132352 | 0.85 | AXL (0.55) | AXLMETKDRPDGFRBPDGFRA | |
| SCHEMBL21083204 | 0.83 | KDR (0.57) | AXLRETMETKDRPDGFRB | |
| SCHEMBL1132195 | 0.83 | AXL (0.62) | AXLMETKDRPDGFRBPDGFRA | |
| SCHEMBL20032544 | 0.82 | AXL (0.61) | AXLMETKDRPDGFRAFGFR2 | |
| SCHEMBL1132738 | 0.81 | AXL (0.51) | AXLRETMETKDRPDGFRB | |
| SCHEMBL1132736 | 0.81 | AXL (0.51) | AXLRETMETKDRPDGFRB | |
| SCHEMBL22960013 | 0.81 | AXL (0.51) | AXLMETKDRPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2287155-B1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-8304427-B2 | Acylthiourea compound or salt thereof, and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-2287155-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE OF THE COMPOUND OR THE SALT | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20110034439-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034439-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | MET, HGF, STAT6 | AXL 568/4885RET 12/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.